Guardant Health, Inc. $GH Shares Sold by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC trimmed its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 9.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 445,530 shares of the company’s stock after selling 48,856 shares during the period. Guardant Health accounts for 1.9% of Aristotle Atlantic Partners LLC’s portfolio, making the stock its 15th biggest position. Aristotle Atlantic Partners LLC’s holdings in Guardant Health were worth $41,154,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of GH. Allworth Financial LP lifted its stake in Guardant Health by 19.5% in the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after buying an additional 138 shares during the last quarter. Eastern Bank lifted its position in Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after purchasing an additional 139 shares during the last quarter. First Pacific Financial boosted its stake in Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock valued at $52,000 after purchasing an additional 139 shares during the period. Xponance LLC boosted its stake in Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after purchasing an additional 199 shares during the period. Finally, Danske Bank A S grew its position in Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after purchasing an additional 200 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $147.33 on Friday. The company has a market capitalization of $19.54 billion, a PE ratio of -43.46 and a beta of 1.59. The stock has a fifty day moving average of $139.41 and a 200-day moving average of $111.95. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GH. JPMorgan Chase & Co. lifted their target price on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Piper Sandler set a $127.00 price target on Guardant Health in a report on Thursday, May 21st. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. BTIG Research upped their price target on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Finally, Wolfe Research assumed coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $160.04.

Insiders Place Their Bets

In related news, Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total value of $255,893.16. Following the completion of the transaction, the director owned 11,048 shares of the company’s stock, valued at approximately $1,449,055.68. This trade represents a 15.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 708,565 shares of company stock worth $90,556,597 in the last quarter. Corporate insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.